| Dr James Tuchschmidt, MD | |
|
3710 Sw Us Veterans Hospital Rd, Portland, OR 97239-2964 | |
| (503) 273-5247 | |
| Not Available |
| Full Name | Dr James Tuchschmidt |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 3710 Sw Us Veterans Hospital Rd, Portland, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083712442 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | G45688 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Tuchschmidt, MD 3710 Sw Us Veterans Hospital Rd, Po Box 1034, Portland, OR 97239-2964 Ph: (503) 273-5247 | Dr James Tuchschmidt, MD 3710 Sw Us Veterans Hospital Rd, Portland, OR 97239-2964 Ph: (503) 273-5247 |
News Archive
A cutting-edge digital tool that will make it cheaper, safer and faster for pharmaceutical companies to predict protein stability - a vital step in the development of new medicines - is being rolled out by scientists from the UK's University of Bath through their spin-out company, BLOC Labs.
Reuters: President Obama is holding "two meetings with Democratic legislators at the White House on Thursday as he pushes for a vote this month on his healthcare overall plan." The first, which was scheduled for 1:30 p.m. EST, "is expected to include 11 left-leaning members and leaders of minority groups in the House of Representatives, a White House spokesman said." The second meeting "is with leaders of the New Democrat Coalition, a group of centrist Democrats. Seven U.S. representatives are expected to attend that meeting" (Zengerle, 3/4).
ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of encouraging initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition. Among the findings reported were responses to SAR3419 – administered as a single agent – among patients with B-cell non-Hodgkin's lymphoma that is refractory to treatment with rituximab (Rituxan®).
Scancell Holdings Plc, the developer of therapeutic cancer vaccines, is pleased to announce preliminary results from Part 1 of the Phase 1/2 clinical trial of its DNA ImmunoBody vaccine in patients with Stage III/IV malignant melanoma.
› Verified 8 days ago
Salona Shrestha, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4805 Ne Glisan St, Portland, OR 97213 Phone: 503-215-2392 | |
Dr. Emmanuel Trungtoan Tavan, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2800 N Vancouver Ave, Suite 230, Portland, OR 97227 Phone: 503-413-2901 | |
Ginevra Lois Liptan, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 6400 Sw Canyon Ct, Ste 100, Portland, OR 97221 Phone: 503-477-9616 Fax: 503-477-9808 | |
Donald Richard Sullivan, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Uhn67, Portland, OR 97239 Phone: 503-494-6949 | |
Dr. Victor Nguyen Pham, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9205 Sw Barnes Rd, Portland, OR 97225 Phone: 503-216-2906 | |
Richa Uppal, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Sw 13th Ave, Portland, OR 97205 Phone: 503-221-0161 Fax: 503-274-1697 | |
Reem Hasan, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Ppv 350, Portland, OR 97239 Phone: 503-494-8562 |